Eli Lilly

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets Wed, October 7, 2026 at 8:19 PM UTC Moderna and Eli Lilly led healthcare stocks high…

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Eli Lilly breaks ground on $6.5B Houston manufacturing plant

Bechtel's manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general contractor.

FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes

The once-weekly treatment could reduce the number of injections by more ⁠than 300 per year compared with once-daily basal insulin, Eli Lilly said.

This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound. Its stock is soaring.

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

Secret contracts reveal undisclosed terms in Trump's drug-pricing deals

Agreements with Pfizer and Eli Lilly include tariff protections, overseas pricing inducements and broad confidentiality clauses.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

What Eli Lilly Was Telling You While It Rationed Its Own Launches

Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It wa…

Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson &…

What Is Shaping Interest in Eli Lilly Stock? (NYSE:LLY)

Eli Lilly (NYSE:LLY) is in focus after a verified corporate update, while sector conditions and broader market themes shape discussion around its operating cur…

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline

Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline

Lilly perseveres in a bad day for drug stocks - plus, Boeing's mixed deliveries

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Promising Healthcare Stocks To Watch Now - September 6th

Eli Lilly and Company, Moderna, and UnitedHealth Group are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcar…

Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly plans to buy privately held ⁠Merida Biosciences for ‌up to $2.88 billion in cash.

Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

The lawsuits target a range of businesses that allegedly marketed ⁠retatrutide products to consumers despite the drug remaining under clinical development.

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Lilly's revenue soars 48%, driven by demand for its GLP-1s

Lilly's sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Stocks making the biggest moves premarket: SpaceX, AMD, Eli Lilly, Disney & more

These are the stocks posting the largest moves premarket.

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

Ozempic maker Novo Nordisk sues US rival over 'materially misleading' ads

Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective. Ozempic maker Novo Nordisk said on Tuesday…